Company / Accounts Receivable
BioNexus Gene Lab Corp Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$505.9K
FY2025
5-year range
$505.9K / $3.4M
FY2021-FY2025
Trend
-63.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $799,674 to $505,885 over the past 2 years.
Based on SEC 10-K filings.
$505,885 in FY2025 with a 3-year CAGR of -43.9%.
Declined from $799,674 to $505,885 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -43.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -43.9%, indicating a declining trend.
- In FY2025, accounts receivable decreased 63.3% year-over-year.
- Peak accounts receivable was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $505.9K | -63.3% |
| FY2024 | $1.4M | +72.1% |
| FY2023 | $799.7K | -72.1% |
| FY2022 | $2.9M | -14.6% |
| FY2021 | $3.4M | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026